You searched for "VEGF"

164 results found

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

RPE atrophy onset in treated nAMD

In this study the authors aim to evaluate the role of various factors for the development of retinal pigment epithelium (RPE) atrophy over a period of five years in patients with nAMD. Fifty-two newly diagnosed nAMD patients with complete absence...

Wet AMD outcomes post cataract surgery

The authors present the findings of a retrospective study looking at the progression of wet age-related macular degeneration (AMD) in patients who underwent cataract surgery. They recruited a series of 111 patients of which 38 were men and 73 were...

Comparison of treatment regimes for APROP

The authors evaluated the risk factors and treatment outcomes of various treatment options for APROP including intra-vitreal anti-VEGF injections, laser treatment and a combination of both. This was an observational study of all consecutive cases of untreated APROP from 2018-19...

Fluorescein angiography and OCT in myopic CNV

Fluorescein angiography (FA) and spectral-domain optical coherence tomography (OCT) are the most common examinations used in the management of anti-VEGF therapy in choroidal neovascularisation (CNV). In comparison to FA, OCT provides a noninvasive evaluation of the macula. Myopic CNV are...

Do bilateral same day intravitreal injections increase the risk of endophthalmitis?

This large retrospective cohort study reviewed all patients who had bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections between April 2012 and August 2017. There were 101,932 procedures performed in 5890 patients. The two most common indications for injections were...

In conversation with Professor Usha Chakravarthy (2018)

Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...

ROP screening criteria

This study aimed to describe a process of identifying birth weight and gestational age screening guidelines in Mongolia using telemedicine for retinopathy of prematurity (ROP) screening. This was a single centre prospective study collecting data from December 2016 to January...

Management of diabetic macular oedema (DMO)

The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...

Injection frequency and anatomic outcomes following conversion to Aflibercept in neovascular AMD patients

This is a retrospective study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Lucentis and / or Avastin who were switched to aflibercept (Eylea). This study was carried out by the Casey Eye Institute retinal clinics, between...

Management of DMO and PDR in 2019

An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...